Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.
Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of selecting an optimal first-line therapy in gastric cancer.
Gastric cancer is a complex disease, and the field continues to evolve, says Janjigian. Notably, updated data or a new trial emerges into the paradigm every 3 to 6 months, Janjigian explains.
Careful consideration is needed when selecting the frontline therapy for a patient with newly diagnosed gastric cancer, Janjigian says. Moreover, initial therapy selection can have a tremendous effect on the patient’s treatment journey and long-term survival. As such, individualized consideration into the optimal agent and dosing regimen are needed to maximize the patient's potential response, while avoiding toxicities and maintaining adequate nutrition.
Gastric cancer encompasses at least 4 to 5 different molecularly distinct subtypes; thus, experts are eager to understand more about the presentation of this disease and is hopeful for what the future holds, Janjigian concludes.